on ABIVAX (EPA:ABVX)
Abivax successfully concludes an ADS offer
Abivax announced the full exercise of its option to subscribe to additional American Depositary Shares (ADS). This brings the gross proceeds of the offering to $920 million (€807 million). The biotechnology company, listed on Euronext Paris and Nasdaq, specializes in therapies for chronic inflammatory diseases.
The initial offering comprised 6.4 million ADSs, with an additional 960,000 ADSs to be added after the exercise of the over-allotment option. Settlement of the ADSs is expected to take place on July 6, 2026. Estimated net proceeds will reach approximately $874.1 million (€767.1 million) after deduction of offering-related expenses.
The funds will be used for marketing expenses in the United States and clinical research related to treatments for ulcerative colitis and Crohn's disease.
R. E.
Copyright © 2026 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all ABIVAX news